Glargine and Regular Human Insulin Similarly Acutely Enhance Endothelium-Dependent Vasodilatation in Normal Subjects

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 2, 2004, Pages 320-324

  Westerbacka, Jukka ^a   Bergholm, Robert ^a   Tiikkainen, Mirja ^a   Yki Järvinen, Hannele ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Arteries; Insulin like growth factor 1; Vasculature

Indexed keywords

ACETYLCHOLINE; FATTY ACID; HUMAN INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR; NITROPRUSSIDE SODIUM; SOMATOMEDIN C RECEPTOR;

ADULT; ARTICLE; BLOOD FLOW; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; VASODILATATION;

ACETYLCHOLINE; ADULT; BLOOD CIRCULATION; BLOOD FLOW VELOCITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; EPIDURAL SPACE; FASTING; HEART RATE; HUMANS; INFUSIONS, INTRA-ARTERIAL; INSULIN; MALE; NITROPRUSSIDE; VASODILATION;

EID: 1042291153     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000110444.59568.56     Document Type: Article

References (30)

1. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-874.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;326:801-809.
3. Steinberg HO, Brechtel G, Johnson A, Fireberg N, Baron AD. Insulin-mediated skeletal muscle vasodilatation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94:1172-1179.
4. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994;94:2511-2515.
5. Taddei S, Virdis A, Mattei P, Natali A, Ferrannini E, Salvetti A. Effect of insulin on acetylcholine-induced vasodilatation in normotensive subjects and patients with essential hypertension. Circulation. 1995;92:2911-2918.
6. Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Nervil KC, et al. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes. 2001;50:2611-2618.
7. Sundell J, Knuuti J. Insulin and myocardial blood flow. Cardiovasc Res. 2003;57:312-319.
8. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626-2632.
9. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;96:1152-1156.
10. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42:1151-1167.
11. Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs. 2000;59:253-260.
12. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758-767.
13. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular-insulin. Horm Metab Res. 1998;30:123-129.
14. Bahr M, Kolter T, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue |GlyA21, ArgB31, ArgB32|insulin (HOE 901) in muscle cells. Eur J Pharmacol. 1997;320:259-265.
15. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-1. J Clin Metab. 2001;86:5838-5847.
16. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999-1005.
17. Pendergrass M, Fazioni E, Collins D, DeFronzo RA. IGF-1 increases forearm blood flow without increasing forearm glucose uptake. Am J Physiol. 1998;275:E345-E350.
18. Mäkimattila S, Virkamäki A, Groop P-H, Cockcroft J, Utriainen T, Fagerudd J, et al. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation. 1996;94:1276-1282.
19. Utriainen T, Malmström R, Mäkimattila S, Yki-Järvinen H. Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia. 1995;38:555-564.
20. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
21. Kadish AH, Little RL, Sternberg JC. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem. 1968;14:116-131.
22. Miles J, Classcock R, Aikens J, Gerich J, Haymond N. A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res. 1983;24:96-99.
23. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res. 1994;28:303-311.
24. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105:576-582.
25. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: randomized controlled study. Diabetes Care. 2000;23:504-509.
26. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130-1136.
27. Vehkavaara S, Mäkimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Järvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000;20:545-550.
28. Gaenzer H, Neumayr G, Marschang P, Sturm W, Lechleimer M, Foger B, et al. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes, mellitus. Am J Cardiol. 2002;89:431-434.
29. Dagogo-Jack S, Askari H, Morrill B, Lehner LL, Kim B, Sha X. Physiological responses during hypoglycaemia induced by regular human insulin of a novel human analogue, insulin glargine. Diabetes Obes Metab. 2000;2:373-383.
30. Mudaliar S, Mohideen P, Deutsch R, Ciaraldi TP, Armstrong D, Kim B, et al. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care. 2002;25:1597-1602.